# A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

> **NCT03997539** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 256 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Treatment of physician's choice
- **DRUG:** vinorelbine

## Key facts

- **NCT ID:** NCT03997539
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-15
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2019-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03997539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03997539, "A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03997539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*